Graft-versus-host disease (GVHd) poses a challenge after allogeneic hematopoietic stem cell transplantation (HSCT), with ciclosporin used for prevention but showing complex variations in metabolism due to factors like inflammation.
A study involving 71 adult HSCT patients assessed the relationship between inflammation levels (measured by C-reactive protein) and ciclosporin metabolism, finding that severe inflammation led to decreased metabolism but did not affect blood levels thanks to dose adjustments.
The study concluded that inflammation significantly impacts ciclosporin pharmacokinetics, emphasizing the need for careful therapeutic monitoring and potential personalized dosage strategies in HSCT patients.
(1) Background: Oral targeted anticancer drugs are victims of presystemic pharmacokinetic drug−drug interactions (DDI). Identification of the nature of these DDIs, i.e.